Effects of growth hormone treatment on cognitive function and head circumference in children born small for gestational age.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Short stature is not the only problem faced by children born small for gestational age (SGA).

Mean age at start of therapy was 7.4 years; mean duration of GH treatment was 8.0 years.

Who Took Part

The abstract describes 79 children taking part.

The age groups tagged for this paper are infants, young children and children, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and parallel-group.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the children and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

What Was Measured

Vocabulary s-score (Verbal IQ) was normal at the start of therapy and remained so over time.

The subject headings attached to it are Cognition, Head, Human Growth Hormone, Infant, Small for Gestational Age, Problem Solving, Self Concept and Speech Intelligibility.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 79 children.

The publication is from 2005 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.